1. Home
  2. PCRX vs EVH Comparison

PCRX vs EVH Comparison

Compare PCRX & EVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • EVH
  • Stock Information
  • Founded
  • PCRX 2006
  • EVH 2011
  • Country
  • PCRX United States
  • EVH United States
  • Employees
  • PCRX N/A
  • EVH N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • EVH Other Consumer Services
  • Sector
  • PCRX Health Care
  • EVH Consumer Discretionary
  • Exchange
  • PCRX Nasdaq
  • EVH Nasdaq
  • Market Cap
  • PCRX 1.2B
  • EVH 1.2B
  • IPO Year
  • PCRX 2011
  • EVH 2015
  • Fundamental
  • Price
  • PCRX $22.90
  • EVH $11.20
  • Analyst Decision
  • PCRX Buy
  • EVH Strong Buy
  • Analyst Count
  • PCRX 8
  • EVH 14
  • Target Price
  • PCRX $28.38
  • EVH $16.79
  • AVG Volume (30 Days)
  • PCRX 545.0K
  • EVH 3.4M
  • Earning Date
  • PCRX 07-29-2025
  • EVH 08-07-2025
  • Dividend Yield
  • PCRX N/A
  • EVH N/A
  • EPS Growth
  • PCRX N/A
  • EVH N/A
  • EPS
  • PCRX N/A
  • EVH N/A
  • Revenue
  • PCRX $702,772,000.00
  • EVH $2,398,737,000.00
  • Revenue This Year
  • PCRX $7.54
  • EVH N/A
  • Revenue Next Year
  • PCRX $10.78
  • EVH $16.14
  • P/E Ratio
  • PCRX N/A
  • EVH N/A
  • Revenue Growth
  • PCRX 3.08
  • EVH 10.24
  • 52 Week Low
  • PCRX $11.16
  • EVH $7.06
  • 52 Week High
  • PCRX $27.64
  • EVH $33.63
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 35.82
  • EVH 63.81
  • Support Level
  • PCRX $22.82
  • EVH $11.54
  • Resistance Level
  • PCRX $23.83
  • EVH $12.07
  • Average True Range (ATR)
  • PCRX 0.74
  • EVH 0.55
  • MACD
  • PCRX -0.02
  • EVH 0.02
  • Stochastic Oscillator
  • PCRX 6.22
  • EVH 69.49

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Share on Social Networks: